OPTIMIZATION OF THERAPEUTIC MEASURES FOR MALIGNANT NEOPLASIA OF THE MAMMARY GLANDS IN CATS

Authors

  • D. Bilyi
  • M. Herhaulov

Keywords:

cats, neoplasms, mammary gland, mastectomy, chemotherapy, nonsteroidal anti-inflammatory drugs, hemostasis system.

Abstract

The relevance of the problem of treating cats with malignant neoplasia of the mammary gland is related to the significant spread of neoplasms; the absolute advantage of their malignant types, which are characterized by high aggressiveness; insufficient treatment efficiency. Adjuvant chemotherapy with docetaxel and cyclophosphamide reduced the risk of disease progression by 1.5 times, its combination with meloxivet – by 2.2 times. Supplementation of the chemotherapeutic protocol with cyclooxygenase-2 inhibitor reduced the probability of recurrence in the thickness of the wound scar and adjacent tissues by 2.1 times, distant soft tissues by 3.1 times, lungs by 1.3 times. The inclusion of the non-steroidal anti-inflammatory drug meloxivet in the chemotherapy protocol for the treatment of cats with malignant mammary gland tumors ensured a faster dynamic reduction of the inflammatory reaction, which was confirmed by a reduction in the recovery time of such hemostasiological parameters as the duration of the activated partial thromboplastin time, prothrombic index, international normalized ratio, as well as fibrinogen content and platelet concentrations.

Author Biographies

D. Bilyi

Dnipro State Agrarian and Economic University

M. Herhaulov

Dnipro State Agrarian and Economic University

References

Beam, S. L., Rassnick, K. M., Moore, A. S., & McDonough, S. P. (2003). An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Veterinary pathology, 40(5), 496–500. doi: 10.1354/vp.40-5-496

Birkbeck, R., Humm, K., & Cortellini, S. (2019). A review of hyperfibrinolysis in cats and dogs. Journal of Small Animal Practice, 60(11), 641-655. doi: 10.1111/jsap.13068

Bishop, B. F., & Ngo, S. N. (2018). Non-Steroidal Anti-Inflammatory Drugs as Chemopreventive Agents: Evidence from Cancer Treatment in Domestic Animals. Annual Research & Review in Biology, 26(1), 1-13. doi: 10.9734/ARRB/2018/40829

Borrego, J. F., Cartagena, J. C., & Engel, J. (2009). Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007). Veterinary and comparative oncology, 7(4), 213–221. doi: 10.1111/j.1476-5829.2009.00194 .x

Carroll, G. L., & Simonson, S. M. (2005). Recent developments in nonsteroidal antiinflammatory drugs in cats. Journal of the American Animal Hospital Association, 41(6), 347–354. doi: 10.5326/0410347

Cassali, G. D., Campos, C. B., Angélica, C. B., Alessandra, E. A., Gleidice, E. L., Karine, A. D., Andrigo, B. D., Bruno, C., Fernanda, V. A. C., Renata, S., Giovana, W. D., Cristina, G. F., Enio, F., Breno, S. S., Carlos, H. C., Danielle, N. S., Emanoel, F. M., Stéfane, V.T., Fernanda, C. N., Karen, Y. R. N. (2018). Consensus for the Diagnosis, Prognosis and Treatment of Feline Mammary Tumors. Brazilian Journal of Veterinary Research and Animal Science, 55(2), 1-17.

Charlton, A. N., Benito, J., Simpson, W., Freire, M., & Lascelles, B. D. (2013). Evaluation of the clinical use of tepoxalin and meloxicam in cats. Journal of feline medicine and surgery, 15(8), 678–690. doi: 10.1177/1098612X12473994

De Groot, D. J. A., De Vries, E. G. E., Groen, H. J. M., & De Jong, S. (2007). Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Critical reviews in oncology/hematology, 61(1), 52-69. doi: 10.1016/j.critrevonc.2006.07.001

de Menine, N. P. M., Araújo, G. G. A. D. S., & Wulff, M. D. L. (2021). Mammary cribriform carcinoma in a feline patient: case report. PUBVET, 15 (9), MC4924

Doré M. (2011). Cyclooxygenase-2 expression in animal cancers. Veterinary pathology, 48(1), 254–265. doi: 10.1177/0300985810379434

Estrin, M. A., Wehausen, C. E., Lessen, C. R., & Lee, J. A. (2006). Disseminated intravascular coagulation in cats. Journal of veterinary internal medicine, 20(6), 1334-1339. doi: 10.1111/j.1939-1676.2006.tb00747.x

Ferreira T, Faustino-Rocha AI, Gaspar VM, Medeiros R, Mano JF, and Oliveira PA (2024) Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: In vitro and in vivo studies, Veterinary World, 17(5): 1052–1072 doi: 10.14202/vetworld.2024.1052-1072

Giménez, F., Hecht, S., Craig, L. E., & Legendre, A. M. (2010). Early detection, aggressive therapy: optimizing the management of feline mammary masses. Journal of feline medicine and surgery, 12(3), 214-224. doi: 10.1016/j.jfms.2010.01.004

Gregório, H., Magalhães, T. R., Pires, I., Prada, J., Carvalho, M. I., & Queiroga, F. L. (2021). The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review. Veterinary medicine and science, 7(4), 1107–1119. doi: 10.1002/vms3.460

Goldschmidt, M. H., Peña, L., & Zappulli, V. (2016). Tumors of the mammary gland. Tumors in domestic animals, 723-765. doi: 10.1002/9781119181200.ch17

Gurpinar, E., Grizzle, W. E., & Piazza, G. A. (2013). COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Frontiers in oncology, 3, 181. doi: 10.3389/fonc.2013.00181

Hughes, K., & Dobson, J. M. (2012). Prognostic histopathological and molecular markers in feline mammary neoplasia. Veterinary journal (London, England : 1997), 194(1), 19–26. doi: 10.1016/j.tvjl.2012.05.008

Kamata, M., King, J. N., Seewald, W., Sakakibara, N., Yamashita, K., & Nishimura, R. (2012). Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial. Veterinary journal (London, England : 1997), 193(1), 114–118. doi: 10.1016/j.tvjl.2011.11.026

Keepman, S. J., & Pellin, M. A. (2022). Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. Journal of feline medicine and surgery, 24(12), 1187–1194. doi: 10.1177/1098612X211067023

Lascelles, B. D. X., Court, M. H., Hardie, E. M., & Robertson, S. A. (2007). Nonsteroidal anti-inflammatory drugs in cats: a review. Veterinary anaesthesia and analgesia, 34(4), 228-250. doi: 10.1111/j.1467-2995.2006.00322.x

Mathews, K. A. (2002). Non‐steroidal anti‐inflammatory analgesics: a review of current practice. Journal of Veterinary Emergency and Critical Care, 12(2), 89-97. doi: 10.1046/j.1435-6935.2002.00007.x

Millanta, F., Citi, S., Della Santa, D., Porciani, M., & Poli, A. (2006). COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast cancer research and treatment, 98(1), 115–120. doi: 10.1007/s10549-005-9138-z

Millanta, F., Asproni, P., Canale, A., Citi, S., & Poli, A. (2016). COX‐2, mPGES‐1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Veterinary and Comparative Oncology, 14(3), 270-280. doi: 10.1111/vco.12096

Morris, J. (2013). Mammary tumours in the cat: size matters, so early intervention saves lives. Journal of feline medicine and surgery, 15(5), 391-400. doi: 10.1177/1098612X13483237

Papich, M. G., & Messenger, K. (2015). Non‐steroidal anti‐inflammatory drugs. Veterinary anesthesia and analgesia: The fifth edition of Lumb and Jones, 227-243. doi: 10.1002/9781119421375.ch12

Peterson, J. L., Couto, C. G., & Wellman, M. L. (1995). Hemostatic disorders in cats: a retrospective study and review of the literature. Journal of Veterinary Internal Medicine, 9(5), 298-303. doi: 10.1111/j.1939-1676.1995.tb01088.x

Petrucci, G. N., Henriques, J., Lobo, L., Vilhena, H., Figueira, A. C., Canadas-Sousa, A., Dias-Pereira, P., Prada, J., Pires, I., & Queiroga, F. L. (2021). Adjuvant doxorubicin vs metronomic cyclophosphamide and meloxicam vs surgery alone for cats with mammary carcinomas: A retrospective study of 137 cases. Veterinary and comparative oncology, 19(4), 714–723. doi: 10.1111/vco.12660

Ralph, A. G., & Brainard, B. M. (2012). Update on disseminated intravascular coagulation: when to consider it, when to expect it, when to treat it. Topics in companion animal medicine, 27(2), 65–72. doi: 10.1053/j.tcam.2012.06.004

Rueda, J. R., Porto, C. D., Franco, R. P., da Costa, I. B., Bueno, L. M. C., Girio, R. J. S., ... & Repetti, C. S. F. (2024). Mammary neoplasms in female dogs: Clinical, diagnostic and therapeutic aspects. Veterinární medicína, 69(4), 99. doi: 10.17221/4/2024-VETMED

Owen LN. TNM Classification of tumors in domestic animals. Geneva: World Health Organization. 1980.

Stancu, A., Cristea, A., & Lescai, D. (2020). Mammary tumors in dogs and cats. Romanian Journal of Veterinary Medicine & Pharmacology, 2 (22), 78-87

Szweda, M., Rychlik, A., Babińska, I., & Pomianowski, A. (2019). Significance of cyclooxygenase-2 in oncogenesis. Journal of Veterinary Research, 63(2), 215-224.

Tsuji, S., Tsujii, M., Kawano, S., & Hori, M. (2001). Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. Journal of experimental & clinical cancer research: CR, 20(1), 117–129.

Published

2024-10-08

How to Cite

Білий, Д., & Гергаулов, М. (2024). OPTIMIZATION OF THERAPEUTIC MEASURES FOR MALIGNANT NEOPLASIA OF THE MAMMARY GLANDS IN CATS. Agrarian Bulletin of the Black Sea Littoral, (112), 11-21. Retrieved from https://abbsl.osau.edu.ua/index.php/visnuk/article/view/582